Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma-Reference-Cited by-同舟云学术

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma

Published:2019-12 Issue: Volume:15 Page:60-68
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Ying Zhitao,He Ting,Wang Xiaopei,Zheng Wen,Lin Ningjing,Tu Meifeng,Xie Yan,Ping Lingyan,Zhang Chen,Liu Weiping,Deng Lijuan,Qi Feifei,Ding Yanping,Lu Xin-an,Song Yuqin,Zhu Jun

Funder

National Natural Science Foundation of China

Beijing Municipal Administration of Hospitals

Beijing Municipal Natural Science Foundation

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference33 articles.

1. Non-Hodgkin lymphoma;Shankland;Lancet,2012

2. New therapies in non-Hodgkin lymphoma;Novelli;Expert Rev. Anticancer Ther.,2015

3. CAR T cell immunotherapy for human cancer;June;Science,2018

4. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors;Kochenderfer;Nat. Rev. Clin. Oncol.,2013

5. CAR T-cells merge into the fast lane of cancer care;Frey;Am. J. Hematol.,2016

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mRNA-based therapeutic strategies for cancer treatment;Molecular Therapy;2024-09

2. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy;Experimental Hematology & Oncology;2024-07-10

3. Altered cancer metabolism and implications for next-generation CAR T-cell therapies;Pharmacology & Therapeutics;2024-07

4. Engineering strategies to mitigate toxicities associated with CAR‐T cell therapy;BMEMat;2024-06-22

5. Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is There Still a Role for Autologous Stem Cell Transplantation in the CAR T-Cell Era?;Cancers;2024-05-23